HONG KONG, Oct. 10, 2013
/PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx:
0460) ("Sihuan Pharmaceutical" or the "Company"), a leading
pharmaceutical company with the largest cardio-cerebral vascular
("CCV") drug franchise in China's
prescription market, announced that the application it had
submitted for Clinical Trial Approval of Pirotinib, a Category 1.1
Innovative Drug developed by the Company's innovative drug research
and development ("R&D") team, was accepted by the China Food
and Drug Administration ("CFDA") (IND filing numbers 1300995 and
1300996). Sihuan Pharmaceutical's first self-developed oncology
drug, Pirotinib, is another milestone in the Company's development
of innovative drugs as it signifies the Company's capability to tap
the oncology products market.
Pirotinib is a second generation (pan-HER) inhibitor for the
treatment of lung cancer and breast cancer. Its preclinical studies
demonstrate that the drug has unique profiles in pharmacology,
pharmacokinetics and toxicology, and features a developable
property. The Company's scientific research team is currently
evaluating the possibility of filing an application for FDA
approval in the United States. In
addition, the Group, having submitted applications for
international patent rights for Pirotinib, has entered the
evaluation process in China,
the United States, Japan and Europe.
Dr. Che Fengsheng, Chairman and CEO of Sihuan
Pharmaceutical, said, "According to statistics from MENET, the
oncology drug market is one of the largest drug markets in
China with a market scale
exceeding RMB 66.7 billion at the end
of 2012. Lung cancer is the top tumour disease in China, while breast cancer ranks sixth, with
mortality rate increasing in recent years. Pirotinib, as a unique
innovative drug designed to cure lung cancer and breast cancer
featuring competitive rates of efficacy, has strong market
potential. It may also provide physicians and patients better
treatment options and will drive the development of the Company in
the field of oncology, which will further consolidate the Company's
diversified product lines and drive its sustainable growth."
About Sihuan Pharmaceutical Holdings Group Ltd.
Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a
leading Chinese pharmaceutical corporation and the largest
cardio-cerebral vascular drug franchise in China's prescription drug market by market
share. The Company also became the third largest pharmaceutical
company in terms of hospital purchase in the Chinese prescription
drug market in the first half of 2013. The success of the Group can
be attributed to its differentiated and proven sales and marketing
model, extensive nationwide distribution network, young and
diversified product portfolio, and strong R&D capabilities. The
company's current products encompass the top five medical
therapeutic areas in China:
cardio-cerebral vascular system, central nervous system,
metabolism, oncology and anti-infectives. Their major products such
as Kelinao, Oudimei, Yuanzhijiu, Yeoduojia, GM1 and Chuanqing are
widely used in the treatment of various cardio-cerebral vascular
diseases.
SOURCE Sihuan Pharmaceutical Holdings Group Ltd.